-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
ARK Investment Management LLC Increases Position in RedHill Biopharma Ltd. (NASDAQ:RDHL)
ARK Investment Management LLC Increases Position in RedHill Biopharma Ltd. (NASDAQ:RDHL)
ARK Investment Management LLC grew its holdings in RedHill Biopharma Ltd. (NASDAQ:RDHL – Get Rating) by 21.3% in the second quarter, Holdings Channel.com reports. The institutional investor owned 1,045,023 shares of the biotechnology company's stock after acquiring an additional 183,225 shares during the quarter. ARK Investment Management LLC's holdings in RedHill Biopharma were worth $1,170,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also made changes to their positions in RDHL. HighTower Advisors LLC purchased a new position in RedHill Biopharma during the fourth quarter worth about $32,000. GSA Capital Partners LLP raised its holdings in RedHill Biopharma by 108.4% during the fourth quarter. GSA Capital Partners LLP now owns 218,338 shares of the biotechnology company's stock worth $563,000 after purchasing an additional 113,584 shares in the last quarter. Gagnon Securities LLC raised its holdings in RedHill Biopharma by 15.4% during the first quarter. Gagnon Securities LLC now owns 367,346 shares of the biotechnology company's stock worth $926,000 after purchasing an additional 49,023 shares in the last quarter. BlackRock Inc. raised its holdings in RedHill Biopharma by 18.6% during the first quarter. BlackRock Inc. now owns 357,493 shares of the biotechnology company's stock worth $901,000 after purchasing an additional 56,178 shares in the last quarter. Finally, Disciplined Growth Investors Inc. MN raised its holdings in RedHill Biopharma by 0.7% during the first quarter. Disciplined Growth Investors Inc. MN now owns 1,950,002 shares of the biotechnology company's stock worth $4,914,000 after purchasing an additional 14,413 shares in the last quarter. 7.74% of the stock is owned by hedge funds and other institutional investors.
Get RedHill Biopharma alerts:RedHill Biopharma Stock Down 7.5 %
NASDAQ RDHL opened at $0.68 on Tuesday. RedHill Biopharma Ltd. has a 52-week low of $0.62 and a 52-week high of $6.50. The firm has a 50-day moving average price of $0.92 and a 200 day moving average price of $1.32. The company has a debt-to-equity ratio of 9.42, a current ratio of 0.98 and a quick ratio of 0.79.
RedHill Biopharma (NASDAQ:RDHL – Get Rating) last posted its quarterly earnings results on Thursday, June 23rd. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.10. RedHill Biopharma had a negative net margin of 110.31% and a negative return on equity of 822.29%. The firm had revenue of $18.24 million during the quarter. During the same period in the prior year, the company earned ($0.53) earnings per share. On average, equities research analysts predict that RedHill Biopharma Ltd. will post -0.83 earnings per share for the current fiscal year.RedHill Biopharma Company Profile
(Get Rating)
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.
Featured Stories
- Get a free copy of the StockNews.com research report on RedHill Biopharma (RDHL)
- Oracle's Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Want to see what other hedge funds are holding RDHL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for RedHill Biopharma Ltd. (NASDAQ:RDHL – Get Rating).
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
ARK Investment Management LLC grew its holdings in RedHill Biopharma Ltd. (NASDAQ:RDHL – Get Rating) by 21.3% in the second quarter, Holdings Channel.com reports. The institutional investor owned 1,045,023 shares of the biotechnology company's stock after acquiring an additional 183,225 shares during the quarter. ARK Investment Management LLC's holdings in RedHill Biopharma were worth $1,170,000 as of its most recent filing with the SEC.
據Holdings Channel.com報道，方舟投資管理有限公司在第二季度增持了紅山生物製藥有限公司(納斯達克代碼：RDHL-GET評級)21.3%的股份。該機構投資者在本季度增持了183,225股後，持有這家生物技術公司的1,045,023股股票。截至最近向美國證券交易委員會提交的文件，方舟投資管理公司持有的紅山生物醫藥股份價值117萬美元。
A number of other institutional investors and hedge funds have also made changes to their positions in RDHL. HighTower Advisors LLC purchased a new position in RedHill Biopharma during the fourth quarter worth about $32,000. GSA Capital Partners LLP raised its holdings in RedHill Biopharma by 108.4% during the fourth quarter. GSA Capital Partners LLP now owns 218,338 shares of the biotechnology company's stock worth $563,000 after purchasing an additional 113,584 shares in the last quarter. Gagnon Securities LLC raised its holdings in RedHill Biopharma by 15.4% during the first quarter. Gagnon Securities LLC now owns 367,346 shares of the biotechnology company's stock worth $926,000 after purchasing an additional 49,023 shares in the last quarter. BlackRock Inc. raised its holdings in RedHill Biopharma by 18.6% during the first quarter. BlackRock Inc. now owns 357,493 shares of the biotechnology company's stock worth $901,000 after purchasing an additional 56,178 shares in the last quarter. Finally, Disciplined Growth Investors Inc. MN raised its holdings in RedHill Biopharma by 0.7% during the first quarter. Disciplined Growth Investors Inc. MN now owns 1,950,002 shares of the biotechnology company's stock worth $4,914,000 after purchasing an additional 14,413 shares in the last quarter. 7.74% of the stock is owned by hedge funds and other institutional investors.
其他一些機構投資者和對衝基金也改變了他們在RDHL的頭寸。HighTower Advisors LLC在第四季度購買了RedHill Biophma的一個新頭寸，價值約3.2萬美元。GSA Capital Partners LLP在第四季度增持了108.4%的紅山生物科技股份。GSA Capital Partners LLP現在持有這家生物技術公司218,338股股票，價值563,000美元，上個季度又購買了113,584股。Gagnon Securities LLC在第一季度將其在RedHill Biophma的持股增加了15.4%。Gagnon Securities LLC現在擁有這家生物技術公司367,346股股票，價值926,000美元，上個季度又購買了49,023股。貝萊德股份有限公司在第一季度增持紅山生物科技18.6%的股份。貝萊德股份有限公司目前持有這家生物技術公司357,493股股票，價值901,000美元，該公司在上個季度又購買了56,178股。最後，Ceduled Growth Investors Inc.在第一季度將其在RedHill Biophma的持股增加了0.7%。在上個季度增持了14,413股後，Acciated Growth Investors Inc.現在持有1,950,002股這家生物技術公司的股票，價值4,914,000美元。7.74%的股票由對衝基金和其他機構投資者持有。
RedHill Biopharma Stock Down 7.5 %
紅山Biophma股價下跌7.5%
NASDAQ RDHL opened at $0.68 on Tuesday. RedHill Biopharma Ltd. has a 52-week low of $0.62 and a 52-week high of $6.50. The firm has a 50-day moving average price of $0.92 and a 200 day moving average price of $1.32. The company has a debt-to-equity ratio of 9.42, a current ratio of 0.98 and a quick ratio of 0.79.
納斯達克rdhl週二開盤報0.68美元。RedHill Biophma Ltd.股價跌至0.62美元的52周低點和6.50美元的52周高點。該公司的50日移動均線價格為0.92美元，200日移動均線價格為1.32美元。該公司的債務權益比為9.42，流動比率為0.98，速動比率為0.79。
RedHill Biopharma Company Profile
紅山生物醫藥公司簡介
(Get Rating)
(獲取評級)
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.
紅山生物製藥有限公司是一家專業的生物製藥公司，主要專注於胃腸道和傳染病。該公司推廣胃腸藥物，包括用於治療患有慢性非癌症疼痛的成人阿片類藥物引起的便祕的Movantik；用於治療成人幽門螺桿菌感染的Talicia；以及用於治療成人旅行者腹瀉的Aemcolo。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on RedHill Biopharma (RDHL)
- Oracle's Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
- 免費獲取StockNews.com關於RedHill Biophma(RDHL)的研究報告
- 甲骨文的短期痛苦可能是你的長期收益
- Lucid看起來像是電動汽車的贏家
- 仍然愛着它：投資者繼續光顧麥當勞
- 聯邦快遞剛剛提供了一個買入機會嗎？
- 自動區重新進入拉力賽模式，新高在望
Want to see what other hedge funds are holding RDHL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for RedHill Biopharma Ltd. (NASDAQ:RDHL – Get Rating).
想看看還有哪些對衝基金持有RDHL嗎？訪問HoldingsChannel.com獲取紅山生物醫藥有限公司(納斯達克代碼：Rdhl-Get Rating)的最新13F備案文件和內幕交易信息。
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
接受《紅山生物報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對RedHill Biophma和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧